
Alphabet's Isomorphic Labs raises $2.1 billion to scale AI drug discovery toward clinical trials
Isomorphic Labs, Alphabet's AI drug discovery unit, has secured $2.1 billion in Series B funding to accelerate its IsoDDE platform toward human clinical trials. The capital injection signals deepening confidence in AI-driven molecular design as a viable path to pharmaceutical innovation, moving beyond computational validation into real-world therapeutic validation. This represents a critical inflection point where AI drug discovery transitions from research curiosity to capital-intensive development, with implications for how biotech and pharma incumbents compete against AI-native competitors in the discovery pipeline.90























